Meiotic Protein SYCP2 Confers Resistance to DNA-damaging Agents Through R-loop-mediated DNA Repair

Overview

Journal Nat Commun

Specialty Biology

Date 2024 Feb 21

PMID 38383600

Authors

Yumin Wang

Boya Gao

Luyuan Zhang

Xudong Wang

Xiaolan Zhu

Haibo Yang

Fengqi Zhang

Xueping Zhu

Badi Zhou

Sean Yao

Aiko Nagayama

Sanghoon Lee

Jian Ouyang

Siang-Boon Koh

Eric L Eisenhauer

Dominique Zarrella

Kate Lu

Bo R Rueda

Lee Zou

Xiaofeng A Su

Oladapo Yeku

Leif W Ellisen

Xiao-Song Wang

Li Lan

Affiliations

Soon will be listed here.

Abstract

Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a meiotic protein in the synaptonemal complex, is aberrantly and commonly expressed in breast and ovarian cancers and associated with broad resistance to DDR drugs. Mechanistically, SYCP2 enhances the repair of DNA double-strand breaks (DSBs) through transcription-coupled homologous recombination (TC-HR). SYCP2 promotes R-loop formation at DSBs and facilitates RAD51 recruitment independently of BRCA1. SYCP2 loss impairs RAD51 localization, reduces TC-HR, and renders tumors sensitive to PARP and topoisomerase I (TOP1) inhibitors. Furthermore, our studies of two clinical cohorts find that SYCP2 overexpression correlates with breast cancer resistance to antibody-conjugated TOP1 inhibitor and ovarian cancer resistance to platinum treatment. Collectively, our data suggest that SYCP2 confers cancer cell resistance to DNA-damaging agents by stimulating R-loop-mediated DSB repair, offering opportunities to improve DDR therapy.

References

Bookman M . Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer. 2005; 15 Suppl 3:212-20. DOI: 10.1111/j.1525-1438.2005.00444.x. View

Sekine M, Enomoto T . Precision medicine for hereditary tumors in gynecologic malignancies. J Obstet Gynaecol Res. 2021; 47(8):2597-2606. DOI: 10.1111/jog.14861. View

Gokduman K . Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes. Curr Drug Targets. 2016; 17(16):1928-1939. DOI: 10.2174/1389450117666160502151707. View

Pommier Y, Nussenzweig A, Takeda S, Austin C . Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022; 23(6):407-427. PMC: 8883456. DOI: 10.1038/s41580-022-00452-3. View

Khanna K, Jackson S . DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001; 27(3):247-54. DOI: 10.1038/85798. View

Jiang X, Li X, Li W, Bai H, Zhang Z . PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019; 23(4):2303-2313. PMC: 6433712. DOI: 10.1111/jcmm.14133. View

Keung M, Wu Y, Vadgama J . PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019; 8(4). PMC: 6517993. DOI: 10.3390/jcm8040435. View

Tarsounas M, Sung P . The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. Nat Rev Mol Cell Biol. 2020; 21(5):284-299. PMC: 7204409. DOI: 10.1038/s41580-020-0218-z. View

Paes Dias M, Moser S, Ganesan S, Jonkers J . Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021; 18(12):773-791. DOI: 10.1038/s41571-021-00532-x. View

10.

Teng Y, Yadav T, Duan M, Tan J, Xiang Y, Gao B . ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB. Nat Commun. 2018; 9(1):4115. PMC: 6175878. DOI: 10.1038/s41467-018-06586-3. View

11.

Crossley M, Bocek M, Cimprich K . R-Loops as Cellular Regulators and Genomic Threats. Mol Cell. 2019; 73(3):398-411. PMC: 6402819. DOI: 10.1016/j.molcel.2019.01.024. View

12.

Ouyang J, Yadav T, Zhang J, Yang H, Rheinbay E, Guo H . RNA transcripts stimulate homologous recombination by forming DR-loops. Nature. 2021; 594(7862):283-288. PMC: 8855348. DOI: 10.1038/s41586-021-03538-8. View

13.

Wei L, Nakajima S, Bohm S, Bernstein K, Shen Z, Tsang M . DNA damage during the G0/G1 phase triggers RNA-templated, Cockayne syndrome B-dependent homologous recombination. Proc Natl Acad Sci U S A. 2015; 112(27):E3495-504. PMC: 4500203. DOI: 10.1073/pnas.1507105112. View

14.

Yang H, Wang Y, Xiang Y, Yadav T, Ouyang J, Phoon L . FMRP promotes transcription-coupled homologous recombination via facilitating TET1-mediated m5C RNA modification demethylation. Proc Natl Acad Sci U S A. 2022; 119(12):e2116251119. PMC: 8944906. DOI: 10.1073/pnas.2116251119. View

15.

Yasuhara T, Kato R, Hagiwara Y, Shiotani B, Yamauchi M, Nakada S . Human Rad52 Promotes XPG-Mediated R-loop Processing to Initiate Transcription-Associated Homologous Recombination Repair. Cell. 2018; 175(2):558-570.e11. DOI: 10.1016/j.cell.2018.08.056. View

16.

Chen H, Yang H, Zhu X, Yadav T, Ouyang J, Truesdell S . mC modification of mRNA serves a DNA damage code to promote homologous recombination. Nat Commun. 2020; 11(1):2834. PMC: 7275041. DOI: 10.1038/s41467-020-16722-7. View

17.

Zhu X, Wang X, Yan W, Yang H, Xiang Y, Lv F . Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response. NAR Cancer. 2021; 3(1):zcab010. PMC: 7984809. DOI: 10.1093/narcan/zcab010. View

18.

Kouznetsova A, Novak I, Jessberger R, Hoog C . SYCP2 and SYCP3 are required for cohesin core integrity at diplotene but not for centromere cohesion at the first meiotic division. J Cell Sci. 2005; 118(Pt 10):2271-8. DOI: 10.1242/jcs.02362. View

19.

Feng J, Fu S, Cao X, Wu H, Lu J, Zeng M . Synaptonemal complex protein 2 (SYCP2) mediates the association of the centromere with the synaptonemal complex. Protein Cell. 2017; 8(7):538-543. PMC: 5498334. DOI: 10.1007/s13238-016-0354-6. View

20.

Wu C, Tuo Y . SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer. Future Oncol. 2018; 15(8):817-826. DOI: 10.2217/fon-2018-0821. View